Lauren A. Byers

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 4550: Tumor cell surface targeting of high-grade neuroendocrine carcinomas

  Cancer Research · 2026-04-03

• Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

  British Journal of Cancer · 2026-04-03

• Abstract 1138: Clinical grade circulating tumor DNA methylation predicts outcome to brigatinib plus local consolidative therapy in patients with ALK rearranged NSCLC - Liquid biopsy correlates from the BRIGHTSTAR trial

  Cancer Research · 2026-04-03

• Abstract 4546: HER2- and TROP2-antibody-drug conjugates in small cell lung cancer cell lines and 3D culture: Efficacy and role of target expression

  Cancer Research · 2026-04-03

• Abstract 4544: Predictive biomarkers and combination strategies to overcome resistance to HER2- and TROP2-directed antibody drug conjugates with topoisomerase I inhibitor payloads in SCLC

  Cancer Research · 2026-04-03

• Abstract 4127: Inferring transcriptomic programs from circulating tumor DNA methylation signatures in small cell lung cancer using RRBS and EM-seq

  Cancer Research · 2026-04-03

• Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity

  JCO Precision Oncology · 2026-04-01

• Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments

  Cancer Research · 2025-12-18

• Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer

  European Radiology · 2025-12-17

• Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer

  Molecular Cancer · 2025-12-02 · 2 citations

• MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

  Cancers · 2025-11-27

• Supplementary Figure 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure 4 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

  2025-11-25

• Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure 3 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure 2 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

  2025-11-25

• Supplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

  2025-11-03

• Data from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

  2025-11-03

• Supplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

  2025-11-03

• Supplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer

  2025-11-03